Extremely long tumor retention, on-demand releasing nano-taxel for eradicating ovarian cancers
Ended Project Grant Awarded Last action
- Award ID
- R44CA228645
- Recipient
-
Theranostec Inc. UEI C1B4H9JHQ3J6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,291,539
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Sacramento, CA 95817, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,496,599 | |
| Amendment | $0 | |
| Amendment | $503,046 | |
| Amendment | $0 | |
| Original award | $291,894 |
Show all 11
Quick answers
Who received award R44CA228645?
R44CA228645 was awarded to Theranostec Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2018.
How much is award R44CA228645 worth?
$2,291,539 has been obligated on R44CA228645.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award